Skip to main content

Table 5 Summary statistics of asthma control (assessed by ACQ) at each time point (per-protocol population)

From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

  Baseline 6 months 12 months Change from baseline to 6 months;
p value
Change from baseline to 12 months;
p value
ACQ total score 2.9 ± 1.1 1.4 ± 1.0 1.6 ± 1.1 −1.5 ± 1.2; P < 0.0001 −1.4 ± 1.1; P < 0.0001
Item 1 2.1 ± 1.6 1.0 ± 1.3 1.1 ± 1.2 −1.1 ± 1.6; P < 0.0001 −1.0 ± 1.7; P < 0.0001
Item 2 3.1 ± 1.7 1.3 ± 1.2 1.5 ± 1.4 −1.8 ± 1.8; P < 0.0001 −1.6 ± 1.9; P < 0.0001
Item 3 3.2 ± 1.4 1.3 ± 1.2 1.5 ± 1.3 −1.9 ± 1.7; P < 0.0001 −1.7 ± 1.7; P < 0.0001
Item 4 3.7 ± 1.6 1.7 ± 1.5 1.8 ± 1.5 −1.9 ± 1.9; P < 0.0001 −1.9 ± 1.8; P < 0.0001
Item 5 3.1 ± 1.8 1.4 ± 1.5 1.6 ± 1.7 −1.7 ± 1.7; P < 0.0001 −1.6 ± 1.9; P < 0.0001
Item 6 1.4 ± 1.2 0.6 ± 1.0 0.6 ± 0.9 −0.8 ± 1.4; P < 0.0001 −0.7 ± 1.2; P < 0.0001
FEV1 pre-bronchodilator (L) 1.7 ± 0.7 2.1 ± 0.9 2.2 ± 1.1 0.4 ± 0.6; P < 0.0001 0.4 ± 0.9; P < 0.0001
Item 7 4.2 ± 1.6 3.0 ± 2.0 3.0 ± 2.0 −1.2 ± 1.8; P < 0.0001 −1.2 ± 2.1; P < 0.0001
  1. Data are presented as mean ± SD
  2. ACQ total score was evaluated using Paired sample t-test; ACQ individual component scores were evaluated using Signed Rank test
  3. P < 0.05 is considered statistically significant
  4. ACQ Asthma Control Questionnaire